高级检索
当前位置: 首页 > 详情页

The miR-383-LDHA axis regulates cell proliferation, invasion and glycolysis in hepatocellular cancer

文献详情

资源类型:
机构: [1]XiangTan City Cent Hosp, Dept Infect Dis, Xiangtan, Peoples R China [2]Edong Healthcare City Hosp Tradit Chinese Med, Inefect Dis Hosp, Huangshi, Peoples R China [3]Univ South China, Hunan Prov Univ, Canc Res Inst, Key Lab Canc Cellular & Mol Pathol, Hengyang 421001, Peoples R China
出处:
ISSN:

关键词: Hepatocellular cancer LDHA MiR-383

摘要:
Objective(s): To explore the correlation between expression patterns and functions of miR-383 and LDHA in hepatocellular cancer (HCC). Materials and Methods: We detected the expression of miR-383 and LDHA in 30 HCC tissues and their matched adjacent normal tissues using qRT-PCR. Then we performed MTT assay, foci formation assay, transwell migration assay, glucose uptake assay and lactate production assay to explore the function of miR-383 in cell proliferation, invasion and glycolysis in HCC cell lines. Luciferase reporter assay was used to explore whether LDHA was a target gene of miR-383. Western blot and qRT-PCR were used to further confirm LDHA was targeted by miR-383. Then the above functional experiments were repeated to see whether the function of LDHA could be inhibited by miR-383. Results: The results of qRT-PCR showed that miR-383 was down-regulated in HCC tissues compared with their matched adjacent normal tissues. Functional experiments showed that overexpression of miR-383 significantly suppressed cell proliferation, invasion and glycolysis. Luciferase reporter assay showed LDHA was a target gene of miR-383 and expression of LDHA was inversely correlated with that of miR-383 in HCC. Besides, increased cell proliferation, invasion and glycolysis triggered by LDHA could be inhibited by overexpression of miR-383 in HCC cell lines. Conclusion: Our study proved that miR-383 is down-regulated in HCC and acts as a tumor suppressor through targeting LDHA. Targeting the miR-383-LDHA axis might be a promising strategy in HCC treatment.

基金:
语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验 4 区 药学
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验 4 区 药学
第一作者:
第一作者机构: [1]XiangTan City Cent Hosp, Dept Infect Dis, Xiangtan, Peoples R China
通讯作者:
通讯机构: [3]Univ South China, Hunan Prov Univ, Canc Res Inst, Key Lab Canc Cellular & Mol Pathol, Hengyang 421001, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43389 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号